@article {D{\textquoteright}Souza2019.12.08.19014167, author = {George D{\textquoteright}Souza and Chirag Dhar and Vishal Kyalanoor and Lokendra Yadav and Mugdha Sharmra and Mohammad Nawaz S and Sweta Srivastava}, title = {High frequency of Exon 20 S768I EGFR mutation detected in malignant pleural effusions: a poor prognosticator of NSCLC?}, elocation-id = {2019.12.08.19014167}, year = {2020}, doi = {10.1101/2019.12.08.19014167}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Lung cancer is the cause of a fourth of all cancer-related deaths. About a third of all lung adenocarcinoma tumours harbour mutations on exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) gene. Detection of these mutations allows for targeted therapies in the form of EGFR Tyrosine kinase inhibitors. In our study, we utilized malignant pleural effusions (MPEs) as {\textquotedblleft}liquid biopsies{\textquotedblright} to detect EGFR mutations when tissue biopsies were unavailable. We showed that a direct sequencing approach was likely to miss SNVs in MPEs. We then optimized an EGFR mutant-specific quantitative polymerase chain reaction-based assay and piloted it on n=10 pleural effusion samples (1 non-malignant pleural effusion as a negative control). 5/9 (55.55\%) samples harboured EGFR mutations with 2/9 (22.22\%) being exon 19 deletions and 3/9 (33.33\%) had the S768I exon 20 mutation. The frequency of the S768I SNV in our study was significantly higher than that observed in other studies (\~{}0.3\%). Utilizing publicly available cBioPortal data, we report that patients with the S768I SNV had a shorter median survival time, progression-free survival time and lower tumor mutation count compared to patients with other EGFR mutations. These data suggest that this point mutation predicts poor prognosis as a result of aggressive disease, though studies in larger cohorts are necessary to confirm these findings. The high frequency of S768I mutations seen in our study also suggests that cancer cells harbouring these mutations may be superior in their ability to migrate, home or reside in pleural fluid.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by a grant from the Advanced Research Wing of the Rajiv Gandhi University of Health Sciences, Bangalore.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no metadata associated with this study. All relevant data files are included as images or supplementary images.}, URL = {https://www.medrxiv.org/content/early/2020/04/09/2019.12.08.19014167}, eprint = {https://www.medrxiv.org/content/early/2020/04/09/2019.12.08.19014167.full.pdf}, journal = {medRxiv} }